2025 Q4 -tulosraportti
Vain PDF
80 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenOn the contrary, it shows that several professional investors believe the technology has potential. The company raised around 300 million kroner in a financing round to further develop its circRNA-platform, and in total they raised around 620 million kroner in the first half of 2026. At the same time, it is important to remember: * Large investments are no guarantee that the stock will rise. * Biotech companies have high risk, and many do not succeed with development. * The investors who participated know that they can lose large parts of their investment if the technology or clinical results do not deliver. So, 300 million kroner in new capital is a positive signal of confidence, but not proof that the stock is cheap or will provide a high return. If you own Circio, I can also provide an assessment of what could drive the share price up or down in the next 6–12 months.
·1 t sittenReading this now in Finansavisen, Was there anyone here who was in this? https://www.finansavisen.no/helse/2026/07/03/8363321/milliardene-glapp-for-karl-johan-jakola-i-prophylix-legger-ned-selskap-etter-testfiasko How would a message look if the heart testing that Circio is currently doing turned out wrong? How much will such a message affect the share price? Great if someone who has been involved in this comments.
·10 t sittenA bit of speculative reading material for the weekend. A detailed timeline with own research mixed with GreatResets. Why it is most likely Eli Lilly behind the feasibility study.... April 2025 Eli Lilly licenses Sangamo's STAC-BBB AAV-capsid for CNS. (Central Nervous System/brain) A capsid that can finally cross the blood-brain barrier. The technology transfer proceeds relatively quickly, and Eli Lilly is now responsible for research, preclinical development, clinical studies, production, and commercialization. ....but something is missing May 2025 ASGCT Circio presents new in vivo data at the world's most important conference for gene and cell therapy. Data shows that circVec significantly improves gene expression from AAV and has the potential to increase efficacy and durability in gene therapy. Summer/Autumn 2025 Big Pharma evaluates new technologies presented at ASGCT. If Eli Lilly has just secured a CNS-AAV-capsid, a technology that can improve AAV expression would be obvious to investigate. October 2025 Circio publishes even stronger AAV data with up to 40 times higher gene expression in the heart than conventional AAV systems. November 2025 Circio announces a fully funded feasibility study with an anonymous Big Pharma. The study includes: AAV, CNS, one specific disease and no obligations yet. Shortly after: Alex Ward (Director, AAV at Eli Lilly and formerly Sangamo) reacts to Circio's post about new AAV results. Before Lilly, he worked at Sangamo Therapeutics as Director for Vector Production and Development, where he was part of the work on the company's AAV platforms. Alex Ward was also a co-author on several scientific abstracts on the development of BBB-penetrating AAV capsids for CNS, including work on the selection and optimization of capsids to cross the blood-brain barrier. Of course, it's just a reaction, but why him? Why him, who knew about and worked with precisely the technology that Lilly later licensed, which then suddenly lacked a counterpart with a high protein expression platform - a small, lesser-known company with under 15 employees? Coincidence? I actually don't know 💰
Do you think there are economic advantages if it were Eli Lilly? Of course, I myself find it exciting who it is, but does it matter that much if it's Eli, Roche, Pfizer, Novartis etc? And if so, what?
·17 t sittenthe phase shifted in June, and people slept through it 🧱 Everyone stared at the price. Few saw what actually happened. The warrant program is complete. NOK 300M in → ~620M raised in H1 → runway until the end of 2030. Over 400 subscribers exercised. Management and employees ate their own food. ♟️ But the cash is not the story. This is the story: 👇 Circio goes from preclinical platform → clinical-stage. The money is earmarked for a two-stage plan — the lead program (circVec-AAV in genetic heart disease) towards IND in 2H 2028, and further to Phase 1/2 efficacy data. They are no longer "a promising lab-case". They are financed all the way to clinic. 🔬 And the context? BMS spent $1.5 billion on Orbital. Lilly spent $2.4 billion on Orna. Both circRNA. Both bought while they were early. Circio runs its own angle — DNA-based circVec, not synthetic — but the same thesis pharma already pays billions for. 💰 Honest? Still preclinical. No human data before 2029. H1 diluted. The stock is brutally volatile. This is not a safe bet. 📉 But the pieces are being laid one by one — capital, clinical path, partners, validation. And most haven't caught on yet. 👀 We know what we own. ♟️🧱🍷
This is for all of you who Love to quibble, point out errors and Hate AI etc. I have written this myself, so it should be a bit EASY TO READ for you all🥰 If you don't understand dialect, I recommend "copy - paste" (uhhh...yes here you might have to use AI) to get it translated to Bokmål🥰 (Almost, just Almost a true copy from Bennyz) The Fa(de)se shifted in June, and people slept through the whole thing. 🫣😴 Everyone sat and stared at the price, hour out and hour in...😳 Few saw what actually happened. The warrant program is complete... NOK 300 mill in → approximately 620 mill raised in the first half → runway all the way to the end of 2030. Over 400 shareholders utilized these warrants. Management, i.e. Wiklund and the rest of the gang ate their own medicine......(here I lost track a bit... but they bought themselves at least😀) And that, ladies and gentlemen (and Crybabies who need everything spoon-fed) is a Very good sign🤑 So what's next now Circio goes from a preclinical platform → to becoming a clinical-stage company. The money is earmarked for a two-stage plan — to get the main program (circVec-AAV in genetic heart disease) towards IND in the second half of 2028, and further to phase 1/2 with efficacy data. They are no longer just "a promising lab-case". They are financed all the way to clinic🏥 Can we be acquired eventually when we know that.... • BMS put 1.5 billion dollars on Orbital. • Lilly put 2.4 billion dollars on Orna.... (this is an agreement that can be worth up to 2.4 billion dollars, referring here to "Krl"'s statements here in the forum) Both within circRNA. Both bought while they were still early. Circio runs its own twist — DNA-based circVec, not synthetic — but builds on the same thesis that pharma already pays billions for🤑💲 Honestly.... Still preclinical🧐🧐... none of us know anything yet. No human data before 2029 (there are quite a few monkeys in here, maybe you can be included in the studies before then?🐒🐵) First half caused dilution (lost some millions there for my part yes) The stock is brutally volatile (you middle-aged guys know what that is.....briefly and simply describes women in menopause📈🫣📉 This is no sure thing, everything can still turn all ways⬆️➡️⬇️⬅️ But the pieces are being laid, one at a time — capital, clinical path, licensing partners and validation... And most haven't caught on yet🫣🙈 We know what we own💲🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
80 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenOn the contrary, it shows that several professional investors believe the technology has potential. The company raised around 300 million kroner in a financing round to further develop its circRNA-platform, and in total they raised around 620 million kroner in the first half of 2026. At the same time, it is important to remember: * Large investments are no guarantee that the stock will rise. * Biotech companies have high risk, and many do not succeed with development. * The investors who participated know that they can lose large parts of their investment if the technology or clinical results do not deliver. So, 300 million kroner in new capital is a positive signal of confidence, but not proof that the stock is cheap or will provide a high return. If you own Circio, I can also provide an assessment of what could drive the share price up or down in the next 6–12 months.
- ·1 t sittenReading this now in Finansavisen, Was there anyone here who was in this? https://www.finansavisen.no/helse/2026/07/03/8363321/milliardene-glapp-for-karl-johan-jakola-i-prophylix-legger-ned-selskap-etter-testfiasko How would a message look if the heart testing that Circio is currently doing turned out wrong? How much will such a message affect the share price? Great if someone who has been involved in this comments.
- ·10 t sittenA bit of speculative reading material for the weekend. A detailed timeline with own research mixed with GreatResets. Why it is most likely Eli Lilly behind the feasibility study.... April 2025 Eli Lilly licenses Sangamo's STAC-BBB AAV-capsid for CNS. (Central Nervous System/brain) A capsid that can finally cross the blood-brain barrier. The technology transfer proceeds relatively quickly, and Eli Lilly is now responsible for research, preclinical development, clinical studies, production, and commercialization. ....but something is missing May 2025 ASGCT Circio presents new in vivo data at the world's most important conference for gene and cell therapy. Data shows that circVec significantly improves gene expression from AAV and has the potential to increase efficacy and durability in gene therapy. Summer/Autumn 2025 Big Pharma evaluates new technologies presented at ASGCT. If Eli Lilly has just secured a CNS-AAV-capsid, a technology that can improve AAV expression would be obvious to investigate. October 2025 Circio publishes even stronger AAV data with up to 40 times higher gene expression in the heart than conventional AAV systems. November 2025 Circio announces a fully funded feasibility study with an anonymous Big Pharma. The study includes: AAV, CNS, one specific disease and no obligations yet. Shortly after: Alex Ward (Director, AAV at Eli Lilly and formerly Sangamo) reacts to Circio's post about new AAV results. Before Lilly, he worked at Sangamo Therapeutics as Director for Vector Production and Development, where he was part of the work on the company's AAV platforms. Alex Ward was also a co-author on several scientific abstracts on the development of BBB-penetrating AAV capsids for CNS, including work on the selection and optimization of capsids to cross the blood-brain barrier. Of course, it's just a reaction, but why him? Why him, who knew about and worked with precisely the technology that Lilly later licensed, which then suddenly lacked a counterpart with a high protein expression platform - a small, lesser-known company with under 15 employees? Coincidence? I actually don't know 💰Do you think there are economic advantages if it were Eli Lilly? Of course, I myself find it exciting who it is, but does it matter that much if it's Eli, Roche, Pfizer, Novartis etc? And if so, what?
- ·17 t sittenthe phase shifted in June, and people slept through it 🧱 Everyone stared at the price. Few saw what actually happened. The warrant program is complete. NOK 300M in → ~620M raised in H1 → runway until the end of 2030. Over 400 subscribers exercised. Management and employees ate their own food. ♟️ But the cash is not the story. This is the story: 👇 Circio goes from preclinical platform → clinical-stage. The money is earmarked for a two-stage plan — the lead program (circVec-AAV in genetic heart disease) towards IND in 2H 2028, and further to Phase 1/2 efficacy data. They are no longer "a promising lab-case". They are financed all the way to clinic. 🔬 And the context? BMS spent $1.5 billion on Orbital. Lilly spent $2.4 billion on Orna. Both circRNA. Both bought while they were early. Circio runs its own angle — DNA-based circVec, not synthetic — but the same thesis pharma already pays billions for. 💰 Honest? Still preclinical. No human data before 2029. H1 diluted. The stock is brutally volatile. This is not a safe bet. 📉 But the pieces are being laid one by one — capital, clinical path, partners, validation. And most haven't caught on yet. 👀 We know what we own. ♟️🧱🍷This is for all of you who Love to quibble, point out errors and Hate AI etc. I have written this myself, so it should be a bit EASY TO READ for you all🥰 If you don't understand dialect, I recommend "copy - paste" (uhhh...yes here you might have to use AI) to get it translated to Bokmål🥰 (Almost, just Almost a true copy from Bennyz) The Fa(de)se shifted in June, and people slept through the whole thing. 🫣😴 Everyone sat and stared at the price, hour out and hour in...😳 Few saw what actually happened. The warrant program is complete... NOK 300 mill in → approximately 620 mill raised in the first half → runway all the way to the end of 2030. Over 400 shareholders utilized these warrants. Management, i.e. Wiklund and the rest of the gang ate their own medicine......(here I lost track a bit... but they bought themselves at least😀) And that, ladies and gentlemen (and Crybabies who need everything spoon-fed) is a Very good sign🤑 So what's next now Circio goes from a preclinical platform → to becoming a clinical-stage company. The money is earmarked for a two-stage plan — to get the main program (circVec-AAV in genetic heart disease) towards IND in the second half of 2028, and further to phase 1/2 with efficacy data. They are no longer just "a promising lab-case". They are financed all the way to clinic🏥 Can we be acquired eventually when we know that.... • BMS put 1.5 billion dollars on Orbital. • Lilly put 2.4 billion dollars on Orna.... (this is an agreement that can be worth up to 2.4 billion dollars, referring here to "Krl"'s statements here in the forum) Both within circRNA. Both bought while they were still early. Circio runs its own twist — DNA-based circVec, not synthetic — but builds on the same thesis that pharma already pays billions for🤑💲 Honestly.... Still preclinical🧐🧐... none of us know anything yet. No human data before 2029 (there are quite a few monkeys in here, maybe you can be included in the studies before then?🐒🐵) First half caused dilution (lost some millions there for my part yes) The stock is brutally volatile (you middle-aged guys know what that is.....briefly and simply describes women in menopause📈🫣📉 This is no sure thing, everything can still turn all ways⬆️➡️⬇️⬅️ But the pieces are being laid, one at a time — capital, clinical path, licensing partners and validation... And most haven't caught on yet🫣🙈 We know what we own💲🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
80 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenOn the contrary, it shows that several professional investors believe the technology has potential. The company raised around 300 million kroner in a financing round to further develop its circRNA-platform, and in total they raised around 620 million kroner in the first half of 2026. At the same time, it is important to remember: * Large investments are no guarantee that the stock will rise. * Biotech companies have high risk, and many do not succeed with development. * The investors who participated know that they can lose large parts of their investment if the technology or clinical results do not deliver. So, 300 million kroner in new capital is a positive signal of confidence, but not proof that the stock is cheap or will provide a high return. If you own Circio, I can also provide an assessment of what could drive the share price up or down in the next 6–12 months.
- ·1 t sittenReading this now in Finansavisen, Was there anyone here who was in this? https://www.finansavisen.no/helse/2026/07/03/8363321/milliardene-glapp-for-karl-johan-jakola-i-prophylix-legger-ned-selskap-etter-testfiasko How would a message look if the heart testing that Circio is currently doing turned out wrong? How much will such a message affect the share price? Great if someone who has been involved in this comments.
- ·10 t sittenA bit of speculative reading material for the weekend. A detailed timeline with own research mixed with GreatResets. Why it is most likely Eli Lilly behind the feasibility study.... April 2025 Eli Lilly licenses Sangamo's STAC-BBB AAV-capsid for CNS. (Central Nervous System/brain) A capsid that can finally cross the blood-brain barrier. The technology transfer proceeds relatively quickly, and Eli Lilly is now responsible for research, preclinical development, clinical studies, production, and commercialization. ....but something is missing May 2025 ASGCT Circio presents new in vivo data at the world's most important conference for gene and cell therapy. Data shows that circVec significantly improves gene expression from AAV and has the potential to increase efficacy and durability in gene therapy. Summer/Autumn 2025 Big Pharma evaluates new technologies presented at ASGCT. If Eli Lilly has just secured a CNS-AAV-capsid, a technology that can improve AAV expression would be obvious to investigate. October 2025 Circio publishes even stronger AAV data with up to 40 times higher gene expression in the heart than conventional AAV systems. November 2025 Circio announces a fully funded feasibility study with an anonymous Big Pharma. The study includes: AAV, CNS, one specific disease and no obligations yet. Shortly after: Alex Ward (Director, AAV at Eli Lilly and formerly Sangamo) reacts to Circio's post about new AAV results. Before Lilly, he worked at Sangamo Therapeutics as Director for Vector Production and Development, where he was part of the work on the company's AAV platforms. Alex Ward was also a co-author on several scientific abstracts on the development of BBB-penetrating AAV capsids for CNS, including work on the selection and optimization of capsids to cross the blood-brain barrier. Of course, it's just a reaction, but why him? Why him, who knew about and worked with precisely the technology that Lilly later licensed, which then suddenly lacked a counterpart with a high protein expression platform - a small, lesser-known company with under 15 employees? Coincidence? I actually don't know 💰Do you think there are economic advantages if it were Eli Lilly? Of course, I myself find it exciting who it is, but does it matter that much if it's Eli, Roche, Pfizer, Novartis etc? And if so, what?
- ·17 t sittenthe phase shifted in June, and people slept through it 🧱 Everyone stared at the price. Few saw what actually happened. The warrant program is complete. NOK 300M in → ~620M raised in H1 → runway until the end of 2030. Over 400 subscribers exercised. Management and employees ate their own food. ♟️ But the cash is not the story. This is the story: 👇 Circio goes from preclinical platform → clinical-stage. The money is earmarked for a two-stage plan — the lead program (circVec-AAV in genetic heart disease) towards IND in 2H 2028, and further to Phase 1/2 efficacy data. They are no longer "a promising lab-case". They are financed all the way to clinic. 🔬 And the context? BMS spent $1.5 billion on Orbital. Lilly spent $2.4 billion on Orna. Both circRNA. Both bought while they were early. Circio runs its own angle — DNA-based circVec, not synthetic — but the same thesis pharma already pays billions for. 💰 Honest? Still preclinical. No human data before 2029. H1 diluted. The stock is brutally volatile. This is not a safe bet. 📉 But the pieces are being laid one by one — capital, clinical path, partners, validation. And most haven't caught on yet. 👀 We know what we own. ♟️🧱🍷This is for all of you who Love to quibble, point out errors and Hate AI etc. I have written this myself, so it should be a bit EASY TO READ for you all🥰 If you don't understand dialect, I recommend "copy - paste" (uhhh...yes here you might have to use AI) to get it translated to Bokmål🥰 (Almost, just Almost a true copy from Bennyz) The Fa(de)se shifted in June, and people slept through the whole thing. 🫣😴 Everyone sat and stared at the price, hour out and hour in...😳 Few saw what actually happened. The warrant program is complete... NOK 300 mill in → approximately 620 mill raised in the first half → runway all the way to the end of 2030. Over 400 shareholders utilized these warrants. Management, i.e. Wiklund and the rest of the gang ate their own medicine......(here I lost track a bit... but they bought themselves at least😀) And that, ladies and gentlemen (and Crybabies who need everything spoon-fed) is a Very good sign🤑 So what's next now Circio goes from a preclinical platform → to becoming a clinical-stage company. The money is earmarked for a two-stage plan — to get the main program (circVec-AAV in genetic heart disease) towards IND in the second half of 2028, and further to phase 1/2 with efficacy data. They are no longer just "a promising lab-case". They are financed all the way to clinic🏥 Can we be acquired eventually when we know that.... • BMS put 1.5 billion dollars on Orbital. • Lilly put 2.4 billion dollars on Orna.... (this is an agreement that can be worth up to 2.4 billion dollars, referring here to "Krl"'s statements here in the forum) Both within circRNA. Both bought while they were still early. Circio runs its own twist — DNA-based circVec, not synthetic — but builds on the same thesis that pharma already pays billions for🤑💲 Honestly.... Still preclinical🧐🧐... none of us know anything yet. No human data before 2029 (there are quite a few monkeys in here, maybe you can be included in the studies before then?🐒🐵) First half caused dilution (lost some millions there for my part yes) The stock is brutally volatile (you middle-aged guys know what that is.....briefly and simply describes women in menopause📈🫣📉 This is no sure thing, everything can still turn all ways⬆️➡️⬇️⬅️ But the pieces are being laid, one at a time — capital, clinical path, licensing partners and validation... And most haven't caught on yet🫣🙈 We know what we own💲🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt